Bragina O D, Tashireva L A, Loos D M, Vtorushin S V, Shulga A A, Konovalova E N, Borodina M E, Chernov V I, Tolmachev V M, Deyev S M
Tomsk Cancer Research Institute, Tomsk, 634009 Russian Federation.
National Research Tomsk Polytechnic University, Tomsk, 634050 Russian Federation.
Acta Naturae. 2024 Apr-Jun;16(2):22-29. doi: 10.32607/actanaturae.27448.
Anatomic visualization and molecular typing of metastatic regional lymph nodes in breast cancer patients are a serious clinical challenge in modern oncology. According to the results of previous studies, [99mTc]Tc-(HE)3-G3 has proven to be a promising diagnostic agent in differentiating the HER2/neu receptor status in primary breast tumors ( < 0.05, Mann-Whitney test). In this regard, the purpose of this study is to explore the possibilities of using [99mTc]Tc-(HE)3-G3 to determine the HER2/neu receptor status in the metastatic axillary lymph nodes (mALNs) of breast cancer patients. The study was conducted using clinical material from 20 breast cancer patients (T2-4N1-3M0-1) before systemic therapy (10 patients with positive and 10 patients with negative HER2/neu expression in mALNs) who underwent SPECT/CT scan 4 h after the administration of [99mTc]Tc-(HE)3-G3. Morphological and immunohistochemical studies of mALNs with assessment of the HER2/neu status were performed on all patients. We found that mALN-to-background and mALN-to-latissimus dorsi muscle ratios for [99mTc]Tc-(HE)3-G3 uptake 4 h after its administration may be used for typing of the HER2/neu status in mALNs of breast cancer patients ( < 0.05, Mann-Whitney test). In that case, sensitivity and specificity for the mALN-to-background ratio were identical at 80%, with the threshold value being > 12.25.
在现代肿瘤学中，对乳腺癌患者转移性区域淋巴结进行解剖可视化和分子分型是一项严峻的临床挑战。根据以往研究结果，[99mTc]Tc-(HE)3-G3已被证明是一种有前景的诊断剂，可用于鉴别原发性乳腺肿瘤中的HER2/neu受体状态（Mann-Whitney检验，P<0.05）。在这方面，本研究的目的是探索使用[99mTc]Tc-(HE)3-G3来确定乳腺癌患者转移性腋窝淋巴结（mALNs）中HER2/neu受体状态的可能性。本研究使用了20例乳腺癌患者（T2-4N1-3M0-1）在全身治疗前的临床资料（mALNs中HER2/neu表达阳性和阴性的患者各10例），这些患者在注射[99mTc]Tc-(HE)3-G3后4小时接受了SPECT/CT扫描。对所有患者的mALNs进行了形态学和免疫组织化学研究，并评估了HER2/neu状态。我们发现，注射[99mTc]Tc-(HE)3-G3后4小时，mALN与本底以及mALN与背阔肌的摄取比值可用于对乳腺癌患者mALNs中的HER2/neu状态进行分型（Mann-Whitney检验，P<0.05）。在这种情况下，mALN与本底比值的敏感性和特异性均为80%，阈值为>12.25。
